Regulus Therapeutics Surges 11% Amid Deutsche Bank Report
November 24, 2014 at 15:20 PM EST
Deutsche Bank initiated coverage on Regulus Therapeutics Inc (NASDAQ: RGLS) in a report issued Monday with a Buy rating and $30 price ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.